Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
Tenax Therapeutics has furnished a press release disclosing its financial results for the quarter ended June 30, 2025, attaching that release as Exhibit 99.1 to this Form 8-K. The company also included an interactive XBRL cover page as Exhibit 104 and reconfirmed that the press release is furnished rather than filed, so it is not subject to Section 18 liability and is not incorporated by reference into other filings except by specific reference. The 8-K itself does not include any numerical financial figures; readers must consult the attached press release for detailed results and metrics.
Tenax Therapeutics, Inc. (TENX) – Form 4 filing: Director Dr. June Sherie Almenoff reported the receipt of 80,000 stock options on 07/01/2025 at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. No common-stock transactions were reported. Following the grant, Dr. Almenoff now directly holds 80,000 newly issued options in addition to previously reported grants of 100,008 options (small lots dated 2022, 2023, and 2025). The filing reflects a routine equity incentive award to a non-employee director; it does not disclose any purchases or sales of TENX common shares.
Tenax Therapeutics (TENX) filed a Form 4 disclosing insider activity by director Michael H. Davidson on 1 July 2025.
- Equity grant: Davidson acquired 80,000 stock options with an exercise price of $5.75. The options become exercisable on 01-Jul-2026 and expire on 01-Jul-2035. No cash was paid at grant (price $0.00).
- Existing derivative holdings: The filing shows additional option positions of 100,000 options at $5.94, two small option lots (4 each) at $3,200 and $992, a 47,500 pre-funded warrant (strike $0.01, no expiration) and a 25,000 warrant (strike $4.50) that will lapse upon the earlier of several milestone events or 08-Aug-2029.
- Common shares: Davidson owns 2,881 shares directly after the reported transaction.
- Total derivative exposure: The table indicates 252,508 derivative securities (options + warrants) now beneficially owned.
No sales or dispositions of Tenax common stock were reported. The transactions appear to be part of routine director compensation and warrant structures related to prior financing rounds.
Tenax Therapeutics, Inc. (TENX) – Form 4 filing dated 07/03/2025
The filing reports equity incentive activity for Robyn Hunter, a director of Tenax Therapeutics. On 07/01/2025 Ms. Hunter received a new stock-option grant for 80,000 shares of common stock at an exercise price of $5.75 per share. The options become exercisable on 07/01/2026 and expire on 07/01/2035. Following this grant she directly holds:
- 80,000 options (strike $5.75; granted 07/01/2025)
- 4 options (strike $992; expiry 06/09/2032)
- 100,000 options (strike $5.94; expiry 12/10/2034)
No open-market purchases or sales of Tenax common shares are reported; all transactions involve derivative securities (stock options). The filing reflects a routine equity award to a non-employee director and does not modify direct share ownership.